174 related articles for article (PubMed ID: 25033809)
1. Ras chaperones: new targets for cancer and immunotherapy.
Kloog Y; Elad-Sfadia G; Haklai R; Mor A
Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
[TBL] [Abstract][Full Text] [Related]
2. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
3. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
4. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
[TBL] [Abstract][Full Text] [Related]
5. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
6. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
7. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Marciano D; Shohami E; Kloog Y; Alexandrovitch A; Brandeis R; Goelman G
J Neurotrauma; 2007 Aug; 24(8):1378-86. PubMed ID: 17711399
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
10. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
12. Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice.
Huang QJ; Liao GC; Zhuang XR; Yang ML; Yao JJ; Deng JH; Zhang YM; Wang Y; Qi XX; Pan DF; Guan Y; Huang ZY; Zhang FX; Liu ZQ; Lu LL
Acta Pharmacol Sin; 2022 Jul; 43(7):1843-1856. PubMed ID: 34845369
[TBL] [Abstract][Full Text] [Related]
13. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
[TBL] [Abstract][Full Text] [Related]
14. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory properties of farnesoids: the new steroids?
Mor A; Aizman E; Chapman J; Kloog Y
Curr Med Chem; 2013; 20(10):1218-24. PubMed ID: 23432580
[TBL] [Abstract][Full Text] [Related]
16. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Biran A; Brownstein M; Haklai R; Kloog Y
Int J Cancer; 2011 Feb; 128(3):691-701. PubMed ID: 20473860
[TBL] [Abstract][Full Text] [Related]
18. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
19. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
Oron T; Elad-Sfadia G; Haklai R; Aizman E; Brazowski E; Kloog Y; Reif S
Dig Dis Sci; 2012 Feb; 57(2):320-6. PubMed ID: 21901261
[TBL] [Abstract][Full Text] [Related]
20. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Katzav A; Kloog Y; Korczyn AD; Niv H; Karussis DM; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
Clin Exp Immunol; 2001 Dec; 126(3):570-7. PubMed ID: 11737078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
